Heart Disease Deaths during the Covid-19 Pandemic

Jeremy S. Faust, MD, MS, corresponding author  
Harvard Medical School, Brigham and Women’s Hospital Department of Emergency Medicine  
Boston, MA  
jsfaust@gmail.com

Zhenqiu Lin, PhD  
Yale New Haven Hospital, Center for Outcomes Research and Evaluation  
New Haven, CT

Harlan M. Krumholz MD, SM  
Yale University School of Medicine,  
Yale New Haven Hospital, Center for Outcomes Research and Evaluation  
New Haven, CT
The SARS-CoV-2 pandemic is associated with a reduction in hospitalization for an acute cardiovascular conditions. In a major health system in Massachusetts, there was a 43% reduction in these types of hospitalizations in March 2020 compared with March 2019. Whether mortality rates from heart disease have changed over this period is unknown.

Accordingly, we assembled data on weekly heart disease deaths in Massachusetts from the National Center for Health Statistics (Centers for Disease Control and Prevention) for 118,356,533 person-weeks from Week 1 (ending January 4) through Week 17 (ending April 25) of 2020. A total of 4,085 heart disease deaths were recorded during this period (incidence rate, 3.5 per 100,000 person-weeks; 95% confidence interval [CI] 3.4 to 3.6), versus 4,209 heart disease deaths over the same period in 2019 (incidence rate, 3.6 per 100,000 person-weeks; 95% CI, 3.5 to 3.7) (incidence rate ratio, 0.97; 95% CI, 0.92 to 1.01) (Figure 1). Covid-19 deaths and overall deaths, for comparison, markedly rose over the study period.

There are several explanations for the findings. Cardiovascular deaths could be coded as Covid-19 deaths, though there is not routine post-mortem SARS-CoV-2 testing of patients who died in non-medical settings, nor instructions to medical officials to presume deaths of unknown cause to be coded as Covid-19-related in Massachusetts. The cardiovascular deaths could be incomplete for 2020, but the CDC reports that these figures are more than 98.3% to 99.3% complete and the final 0.7% to 1.7% is unlikely to change the conclusion (Supplementary Appendix, Table S1). There could be an actual decline in acute cardiovascular conditions as a result of changes in exposures and behaviors, but the observed >40% decline in hospitalizations, while large, is not associated with a decline in cardiovascular deaths.

These findings add more information to the pursuit of understanding the change in cardiovascular healthcare utilization during the Covid-19 outbreak in the United States but fails to identify a cause. For now, the information is at least reassuring that there was not a marked increase in cardiovascular deaths in Massachusetts during the early phase of the outbreak.

References


Figure 1. Incidence of Heart Disease deaths before and during the Covid-19 Pandemic in 2020 and during the Same Period in 2019, Relative to the Incidence of deaths from Covid-19 and All-Cause Deaths during 2020.

Shown are data from Massachusetts. The data shown in orange are the reported weekly incidence rates of heart disease per 100,000 person-weeks during the period from Week 1 through Week 17, 2020. The data shown in blue are the reported weekly incidence rates of heart disease per 100,000 person-weeks during the period from Week 1 through Week 17, 2019. Bars indicate 95% confidence intervals. The data shown in gray are the rates for Covid-19 deaths per 100,000 person-weeks for the same period, with the first Massachusetts death reported March 26, 2020. The data shown in yellow are the numbers of all-cause deaths per 100,000 person-weeks.